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Background. Alterations in DNA methylation in cancer include global hypomethylation and gene-specific hypermethylation. It
is not clear whether these two epigenetic errors are mechanistically linked or occur independently. This study was performed
to determine the relationship between DNA hypomethylation, hypermethylation and microsatellite instability in cancer.
Methodology/Principal Findings. We examined 61 cancer cell lines and 60 colorectal carcinomas and their adjacent tissues
using LINE-1 bisulfite-PCR as a surrogate for global demethylation. Colorectal carcinomas with sporadic microsatellite
instability (MSI), most of which are due to a CpG island methylation phenotype (CIMP) and associated MLH1 promoter
methylation, showed in average no difference in LINE-1 methylation between normal adjacent and cancer tissues.
Interestingly, some tumor samples in this group showed increase in LINE-1 methylation. In contrast, MSI-showed a significant
decrease in LINE-1 methylation between normal adjacent and cancer tissues (P,0.001). Microarray analysis of repetitive
element methylation confirmed this observation and showed a high degree of variability in hypomethylation between
samples. Additionally, unsupervised hierarchical clustering identified a group of highly hypomethylated tumors, composed
mostly of tumors without microsatellite instability. We extended LINE-1 analysis to cancer cell lines from different tissues and
found that 50/61 were hypomethylated compared to peripheral blood lymphocytes and normal colon mucosa. Interestingly,
these cancer cell lines also exhibited a large variation in demethylation, which was tissue-specific and thus unlikely to be
resultant from a stochastic process. Conclusion/Significance. Global hypomethylation is partially reversed in cancers with
microsatellite instability and also shows high variability in cancer, which may reflect alternative progression pathways in
cancer.
Citation: Este ´cio MRH, Gharibyan V, Shen L, Ibrahim AEK, Doshi K, et al (2007) LINE-1 Hypomethylation in Cancer Is Highly Variable and Inversely
Correlated with Microsatellite Instability. PLoS ONE 2(5): e399. doi:10.1371/journal.pone.0000399
INTRODUCTION
Cancer is a complex disease, which arises from both genetic and
epigenetic errors. The importance of genetic alterations in cancer,
including chromosome abnormalities and genetic mutations as
well its causative factors (e.g. ionizing radiation and chemical
carcinogens) are now well known. The epigenetic component of
cellular transformation, however, was until recently poorly
understood. It has been known for decades that genome-wide
hypomethylation happens in tumors compared to normal cells [1–
4] and overexpression of oncogenes was postulated to be a result of
this hypomethylation. DNA hypermethylation in cancer gained
attention a few years later with studies from Baylin et al. [5,6] and
Jones et al. [7]. The latter alteration occurs in CpG island
promoters of single-copy genes and impairs gene transcription,
resulting in silencing of tumor supressor genes. Several studies
described a tissue-specific pattern of methylation in cancer and
hundred of targets genes are known, including tumor suppressor
genes and genes involved in invasion, angiogenesis and apoptosis
[8,9]. The age-related nature of promoter hypermethylation in
normal tissues [10] has been proposed as a predisposition factor in
cancer.
An important and unsolved question is whether genome-wide
hypomethylation and single-copy CpG island promoter hyper-
methylation are two independent alterations or if they are
mechanistically linked. Unbiased studies of DNA methylation
changes have identified both frequent hypermethylation and
hypomethylation in several types of neoplasia [11–14]. Attempts to
answer this question resulted in contradictory findings, with some
groups supporting [15,16] and others refuting [17,18] a link
between both alterations.
Here, we conducted a genome-wide methylation study in cancer
cell lines and primary tumors to determine the relationship
between DNA hypomethylation, hypermethylation and micro-
satellite instability in cancer. The retrotransposable element LINE-
1 was used as a surrogate of genome-wide hypomethylation, and
methylation microarrays expanded our analysis to other classes of
repetitive elements. Genome-wide methylation differed in co-
lorectal carcinomas belonging to distinct CpG island methylation
phenotype (CIMP) groups, most notably in the ones with
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was infrequent compared to both CIMP+/MSI-and CIMP-/MSI-
groups. Cancer cell lines exhibited a large variation in genome-
wide demethylation, which was tissue-specific and thus unlikely
to be a stochastic process. In summary, our results show that
genome-wide hypomethylation in cancer is highly variable, the
causes of which are unknown, and the existence of a strong inverse
link between global hypomethylation and microsatellite instability
in cancer.
MATERIALS AND METHODS
Tissue samples and cell lines
Sixty matched pairs of tumor and apparently normal adjacent
colon specimens were obtained from patients treated at Johns
Hopkins University (Baltimore, MA). CpG island methylation
phenotype (CIMP) and microsatellite analysis were previously
determined for these samples [19]. Peripheral blood lymphocytes
were obtained from five healthy donors, and normal colon mucosa
tissue was ressected from five individuals submitted to surgery for
gun shot wounds or non-malignant lesions. This study was
approved by the Ethics Committee of Johns Hopkins University
(Baltimore, MA), and informed consent was obtained from all
participants.
Sixty-one cancer cell lines from eight different tissues (breast,
central nervous system, colon, leukemia, liver, lung, ovary and
prostate) were obtained from the American Type Culture Collec-
tion (ATCC, Manassas, VA) and cultured using standard methods.
DNA from patients and cell lines was extracted using standard
phenol–chloroform extraction methods.
Bisulfite-pyrosequencing LINE-1 analysis
Bisulfite treatment was performed as reported [20]. Methylation
analysis of LINE-1 promoter (GenBank accession number
X58075) was investigated using a pyrosequencing-based methyla-
tion analysis. We carried out 50 ml PCR in 60 mM Tris–HCl
pH 8.5, 15 mM ammonium sulfate, 2 mM MgCl2, 10% DMSO,
1 mM dNTP mix, 1 unit of Taq polymerase, 5 pmol of the
forward primer (59-TTTTTTGAGTTAGGTGTGGG-39), 5
pmol of the reverse-biotinylated primer (59-BIO-TCTCACTAA-
AAAATACCAAACAA-39) and 50 ng of bisulfite-treated genomic
DNA. PCR cycling conditions were 95uC for 30 s, 50uC for 30 s
and 72uC for 30s for 50 cycles. The biotinylated PCR product
was purified and made single-stranded to act as a template in
a pyrosequencing reaction as recommended by the manufacturer
using the Pyrosequencing Vacuum Prep Tool (Pyrosequencing,
Inc., Westborough, MA). In brief, the PCR product was bound to
Streptavidin Sepharose HP (Amersham Biosciences, Uppsala,
Sweden) and the Sepharose beads containing the immobilized
PCR product were purified, washed, denatured using a 0.2 M
NaOH solution, and washed again. Then, 0.3 mM pyrosequenc-
ing primer (59-GGGTGGGAGTGAT-39) was annealed to the
purified single-stranded PCR product and pyrosequencing was
performed using the PSQ HS 96 Pyrosequencing System
(Pyrosequencing, Inc.).
Methylated CpG island amplification (MCA)/CpG
island microarray
Sixteen colorectal tumors were compared to their normal appear-
ing adjacent tissue using a CpG island microarray protocol
developed in our laboratory. For each sample, MCA amplicons
were produced according Toyota et al. [20] using RXMA PCR
adaptors. To minimize amplification bias due to differential
incorporation of fluorescent dyes, we opted for an indirect-labeling
protocol. For this, the incorporation of amino-allyl dUTP (aa-
dUTP, Sigma) into 600 ng each of tumor DNA and normal DNA
was conducted using the Bioprime DNA-labeling system protocol
(Life Technologies). Cy5 and Cy3 fluorescent dyes were coupled to
aa-dUTP-labeled tumor and normal adjacent amplicons, re-
spectively, and cohybridized to the HCGI12K-Human CpG 12K
Array (Microarray Centre, University Health Network, Toronto,
Canada). Hybridization and post-hybridization washing proce-
dures are according to DeRisi and colleagues and can be found at
http://www.microarrays.org. Hybridized slides were scanned with
the GenePix 4000A scanner (Axon Instruments, Foster City, CA)
and the acquired images were analyzed with the software GenePix
Pro 6.0. Only spots with annotated DNA sequence with 90% or
more of their length overlapping a repetitive element were used
for analysis. A total of 770 spots representing repetitive DNA of
different classes were evaluated using this method and the
methylation data for each spot was represented as the log2ratio
of tumor (Cy5, red)/normal (Cy3, normal) intensities. Values$1.0
(2-fold change) were indicative of increased methylation (hyper-
methylation) and values#21.0 were indicative of decreased
methylation (hypomethylation) in tumor. Unsupervised hierarchi-
cal clustering was done using the program CIMminer (http://
discover.nci.nih.gov/cimminer/) with calculation for distance
using absolute correlation and complete linkage clustering.
Statistical analysis
The significance of the differences observed between means was
estimated using two-sided Student’s t-test. P value of less than 0.05
was considered statistically significant. One-way ANOVA was
used when comparing similarity for three or more groups.
Statistical analyses were carried out with Statistica software
package (StatSoft, Tulsa, OK).
RESULTS
LINE-1 methylation in colorectal carcinomas
correlates with MSI status
We applied the pyrosequencing method to determine the
methylation density in the LINE-1 promoter. In previous studies,
we validated the application of this method to evaluate genome-
wide methylation content [21,22] and showed a strong positive
correlation between LINE-1 methylation and LC-MS (liquid
chromatography/mass spectrometry) data. Thus, LINE-1 methy-
lation levels can be used as a surrogate of genome-wide demethy-
lation. The map of the LINE-1 promoter with primers and probe
positions is presented in Figure 1A. This method relies on bisulfite
treatment of DNA which modifies unmethylated cytosines to
tymidines while methylated cytosines are non-reactive. PCR of
bisulfite-treated DNA results in pools of products containing both
methylated and unmethylated DNA that can be discriminated and
quantitated using the pyrosequencing method. Representative
LINE-1 pyrograms are presented in Figure 1B. We investigated
five normal colon mucosa and five peripheral blood lymphocyte
(PBL) DNA samples from healthy donors to determine the normal
levels of LINE-1 methylation. The LINE-1 methylation was
similar in these two different tissues, with an average of 71.9% in
PBL and 70.8% in normal colon mucosa.
We next evaluated LINE-1 methylation in sixty primary
colorectal carcinomas and their normal matching mucosa and
correlated this with demographic, clinopathologic and molecular
variables (Table 1). Colorectal tumors averaged 54.9% methyla-
tion (SEM=1.1%) versus 64.3% (SEM=0.5%) methylation in
adjacent normal tissue, corresponding to an average relative
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lation in normal colon, which averaged 70.8% (SEM=1.3%),
both tumor and adjacent to tumor colon mucosa were demethy-
lated, with a respective average of 22.5% and 9.2% relative
demethylation (P=0.001). No differences in LINE-1 methylation
were found by age or gender, but a significant difference was
found for side, with lower levels of methylation in normal adjacent
right colon (63.0%) compared to left colon (65.5%, P=0.016) and
stage, with lower levels of methylation for tumors in stages 3 and 4
(51.9%) compared to stages 0 to 2 (57.1%, P=0.028).
The primary colorectal tumors presented a high variation in
LINE-1 methylation among different samples (Figure 2A), and the
stratification of these colorectal tumors and their normal adjacent
tissue reveals a non-uniform variability in LINE-1 methylation.
CRC with sporadic microsatellite instability (MSI), most of which
are due to MLH1 promoter methylation, showed no difference in
LINE-1 methylation between normal adjacent and cancer tissues
(62.6%61.1% versus 60.6%61.7%, P=0.33), with an average
decrease in methylation of only 3.12%62.3%. By contrast MSI-
cases had a significant decrease in LINE-1 hypomethylation
between normal adjacent and cancer tissues (64.6%60.5% versus
53.8%61.2%, P,0.0001). Apparently, LINE-1 hypomethylation
was independent from CIMP status, since CIMP+/MSI-cases and
CIMP-cases were equally hypomethylated (15.4%62.7% versus
17.7%62.7%, P=0.56). This unequal distribution of relative
demethylation by presence of microsatellite instability is repre-
sented in the Figure 2B, which illustrates the maintenance of
LINE-1 methylation in CIMP+/MSI+tumors compared to normal
appearing mucosa, while CIMP+/MSI-and CIMP-/MSI-undergo
severe hypomethylation, with one case presenting an extreme
relative demethylation (61.3%).
Methylation analysis of repetitive elements using
MCA/CpG island microarrays
In addition to LINE-1 methylation analysis by bisulfite PCR and
pyrosequencing, we also evaluated the methylation status of
repetitive elements including LINE (long interspersed nuclear
elements), SINE (short interspersed nuclear elements), LTR (long
terminal repeats), DNA and satellite repeats, by coupling MCA
(methylated CpG island amplification; 20) to a CpG island
Figure 1. Quantitation of DNA methylation using bisulfite LINE-1 PCR
and pyrosequencing. A) Diagram of the CpG island promoter (GenBank
accession no. X58075, nucleotide position 108–520 bp) associated with
the full length LINE-1. Each vertical line represents a single CpG site.
The 39UTR, 59UTR and two ORFs of LINE-1 are shown at the top. Arrows
indicate the location of primers used for bisulfite PCR (R-biot and F) and
pyrosequencing (S). B) Representative LINE-1 pyrograms for normal
peripheral blood lymphocytes (PBL) and breast cancer cell lines (MB-468
and SKBR3). The pyrogram quantitates C for methylated and T for
unmethylated DNA. The shaded region represents the CpG site
quantitated in LINE-1 elements, and the percent methylation is shown
above the peak.
doi:10.1371/journal.pone.0000399.g001
Table 1. Methylation density of LINE-1and clinical and
demographic characteristics of 60 colorectal carcinomas and
their normal appearing adjacent mucosa*
......................................................................
Variable N Normal Cancer
Mean 95% CI P
a Mean 95% CI P
Subjects
Patients 64.3 63.3–65.3 0.001 54.9 52.7–57.2 0.001
Controls 71.5 68.9–74.0
Age
60 and younger 13 62.8 60.3–65.3 0.142 53.8 49.0–58.7 0.595
more than 60 47 64.7 63.7–65.7 55.2 52.6–57.9
Gender
male 44 64.3 63.3–65.3 0.989 55.1 52.3–57.9 0.738
female 16 64.3 61.9–66.7 54.4 50.6–58.2
Side
b
left 24 65.5 64.2–66.8 0.016 56.8 53.5–60.0 0.173
right 26 63.0 61.4–64.6 53.2 50.6–56.8
Stage
0t o2 35 65.0 63.7–66.2 0.139 57.1 54.5–59.7 0.028
3 and 4 21 63.4 61.6–65.2 51.9 48.0–55.8
MSI status
negative 50 64.6 63.6–65.7 0.117 53.8 51.3–56.3 0.004
positive 10 62.6 60.1–65.1 60.6 56.8–64.4
CIMP status
negative 27 63.9 62.5–65.3 0.458 52.5 48.9–56.2 0.057
positive 33 64.6 63.3–66.0 56.9 54.2–59.6
CIMP/MSI
CIMP+/MSI+ 10 62.6 60.1–65.1 0.087 60.6 56.8–64.4 0.038
CIMP+/MSI- 23 65.5 63.9–67.1 55.3 51.7–58.8
CIMP-/MSI- 27 63.9 62.5–65.3 52.5 48.9–56.2
*Means of cancer methylation is significantly (P,0.001) lower than mean of
adjacent normal for all categories except for MSI+cancers (p=0.24)
aSignificant P values (,0.05) are underlined
bSide information was not available for all cases
CI=confidence interval
doi:10.1371/journal.pone.0000399.t001
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Global Demethylation in Cancer
PLoS ONE | www.plosone.org 3 May 2007 | Issue 5 | e399microarray containing a total of 770 spots representing repetitive
DNA of different classes. The first analysis was performed by
counting hypermethylated (log2ratio,1.0) and hypomethylated
(log2ratio,21.0) repeats separated according to their different
classes (Figure 3A). For the CIMP+/MSI+samples, each one of the
repeats classes except satellite repeats were found to be enriched
for hypermethylation in tumor DNA compared to normal
adjacent mucosa (hypermethylation/hypomethylation=2.4-fold
in average). The enrichment for hypermethylated sequences
decreased sharply in CIMP+/MSI-and CIMP-/MSI-(0.88-and
0.71-fold, respectively). These findings suggest that there is a strong
pressure for maintenance and/or de-novo methylation of repeti-
tive elements in the MSI+group. Validation of our microarray
method was done by comparing the results for LINE-1 to pyro-
sequencing data in the same colorectal samples. This analysis
revealed that tumors with the lowest LINE-1 demethylation by
pyrosequencing analysis showed the highest enrichment for hyper-
methylated LINE repeats (Figure 3B), with the inverse situation
being observed for tumors with the highest LINE-1 demethylation.
These results support that our microarray analysis is a suitable
technique to access methylation changes in repetitive elements.
Finally, using the normalized log2ratio values of individual
spots, we performed unsupervised hierarchical clustering to reveal
the similarities among the 16 colorectal tumor cases studied. The
resulting clustered image map showed a good concordance with
the expected segregation of individual samples by known CIMP/
MSI status (Figure 3C), suggesting that the methylation signatures
of these tumors are not restricted to single-copy genes but also
involve repetitive DNA elements.
Hypomethylation of LINE-1 in cancer cell lines shows
tissue-specific variability
To verify if the variability in genome-wide methylation is restricted
to primary colorectal carcinomas or also occurs in other tumor
types, we applied the LINE-1 bisulfite-pyrosequencing method to
sixty-one cancer cell lines from eight different tissues types (breast,
central nervous system, colon, leukemia, lung, ovary, prostate and
liver). Interestingly, we found a marked decrease in LINE-1
methylation in most of the studied cell lines (Figure 4). Overall,
50/61 tested cancer cell lines were hypomethylated for LINE-1,
with a relative demethylation of 15% or more (absolute methyla-
tion density lower than 60%) compared to peripheral blood
lymphocytes and normal colon mucosa. Similarly to primary
colorectal tumors, these cancer cell lines exhibited high variability
in LINE-1 methylation, ranging from 6.5% (K562, a CML cell
line with erythroleukemia features) to 74.2% (CEM, an acute
lymphoblastic leukemia cell line). There is an apparent tissue-
specificity for demethylation; the lowest levels of LINE-1 methyla-
tion were observed in liver (24.0%), followed by CNS (28.9%),
breast (29.8%), lung (35.1%), prostate (41.9%), ovary (49.7%),
colon (46.7%) and leukemia (56.1%). While an interesting finding,
we caution generalization of the data because: (i) LINE-1 methyla-
tion was not studied for normal tissues except colon and peripheral
blood; and (ii) a small number of cell lines were analyzed for liver
and prostate cancer.
Another significant finding is that some cell lines show extreme
hypomethylation. While leukemias in general present LINE-1
methylation levels equal to PBL, 3/15 cell lines have more than
50% relative demethylation (K562, HEL and TF-1). A similar
situation is observed in other tissues, were ‘‘demethylation cham-
pions’’ cell lines were identified (SKBR3 in breast and OVCA420
in ovarian). An attractive explanation is that genes involved in
DNA methylation maintenance are missing or mutated in these
cell lines.
DISCUSSION
DNA methylation plays an important role in normal cells, being
involved in X-chromosome inactivation, imprinting and repres-
sion of repetitive elements such as retrotransposons and endog-
enous retroviruses [23,24]. At the same time, CpG islands in the
promoter region of single-copy genes are methylation-free, which
is important to allow transcription. In cancer, a reverse scenario
is found, with single-copy CpG island hypermethylation and
genome-wide hypomethylation. The aim of the present work was
to determine the relationship between these two abnormal events,
using cancer cell lines from several tissue-types and primary
colorectal tumors as a model.
Figure 2. Differential LINE-1 methylation among CIMP/MSI groups in
primary colorectal carcinoma samples (CRCs). A) Colorectal tumor DNA
and their normal appearing adjacent mucosa from sixty patients were
evaluated for LINE-1 methylation. These tumors were previously
evaluated for CpG island methylator phenotype (CIMP), using a panel
of single-copy genes methylation analysis, and microsatellite instability
(MSI) status, resulting in the identification of three CIMP/MSI groups. In
normal appearing mucosa (top) little variation in LINE-1 methylation is
observed between samples and CIMP/MSI groups (average methyla-
tion=64.3%), while in tumor (bottom) several samples undergo high
LINE-1 demethylation (25/60 tumor samples have methylation density
bellow 55%), most notable in CIMP+/MSI-and CIMP-/MSI-groups. B)
Relative LINE-1 demethylation in CRCs. Relative demethylation was
calculated as the percent change of LINE-1 methylation in tumor
compared to its normal appearing mucosa. Both CIMP+/MSI-and CIMP-/
MSI-samples presented in average 16% demethylation for LINE-1, while
no significant changes were observed for the CIMP+/MSI+samples. For
the CIMP+group, 4–9% increase of methylation density for LINE-1 was
observed for a small fraction of samples, most of them identified as
CIMP+/MSI+samples.
doi:10.1371/journal.pone.0000399.g002
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hypermethylation occur in cancer, it is poorly understood whether
these two alterations are linked. Our data based on methylation
levels of repetitive elements, using both a specific assay for LINE-1
methylation analysis and a microarray platform comprising almost
800 repetitive DNA sequences from different classes, show that
those tumors with the highest levels of aberrant hypermethylation
(CIMP+/MSI+), also showed the lowest levels of genome-wide
hypomethylation, compared to normal adjacent mucosa. Indeed,
these tumors showed frequent increase in methylation of repetitive
elements, as revealed by both LINE-1 and microarray analysis.
Interestingly, CIMP+/MSI-and CIMP-/MSI-showed higher lev-
els of LINE-1 hypomethylation, reinforcing the uniqueness of
CIMP+/MSI+tumors. Although, CIMP+/MSI-and CIMP-/MSI-
groups were equally hypomethylated for LINE-1, suggesting that
microsatellite instability is the main molecular alteration associated
with lack of LINE-1 hypomethylation. These findings are
concordant with previous reports of lack of global hypomethyla-
tion in microsatellite unstable tumors [15]. The consensus
interpretation of these data is that colorectal tumors arise from
two distinct progression pathways: global hypermethylation with
microsatellite instability and global hypomethylation with chro-
mosome instability. However, it is necessary to note that the
CIMP+/MSI+group is not only characterized by microsatellite
instability, but also for a higher frequency of hypermethylated
CpG islands. Indeed, the causative factor of the observed micro-
satellite instability is the exclusive hypermethylation of MHL1 in
these tumors, and other genes like p16 and THBS1 are also found
more frequently methylated in CIMP+/MSI+compared to
CIMP+/MSI-[25]. In addition, the microarray analysis of
Figure 3. Methylated CpG Island Amplication (MCA)/CpG island microarray for repetitive DNA sequences. A) Relative abundance of hypermethylated
and hypomethylated repeats for each CIMP/MSI group. A higher number of hypermethylated compared to hypomethylated repeats was observed for
the CIMP+/MSI+group, and a gradual change in representation of hypermethylated and hypomethylated repeats was seen for the CIMP+/MSI-and
CIMP-/MSI-groups, resulting in an overrepresentation of hypomethylated repeats in microsatellite stable groups. B) Validation of microarray results
for LINE repeats. Note that CIMP/MSI groups with higher demethylation, as determined by bisulfite-pyrosequencing of LINE-1, presented also a higher
number of hypomethylated LINE repeats by microarray analysis, as represented by a lower hyper/hypomethylation ratio. C) Unsupervised hierarchical
clustering was applied to methylation data from a set of 770 repetitive DNA sequences across sixteen colorectal tumors paired with their normal
appearing mucosa DNA. The colorectal tumors dendrogram is shown, and the sample ID for each case is included in the right. The terminal branches
are color coded to represent the CIMP/MSI status of the tumor sample (red, CIMP+/MSI+; blue, CIMP+/MSI-; green, CIMP-/MSI-). Overall, samples of
the same CIMP/MSI group clustered together, reinforcing the different methylation fate for repetitive DNA sequences methylation in each group.
LINE, long interspersed nuclear elements; SINE, short interspersed nuclear elements, LTR, long terminal repeats; DNA repeats; Satellite repeats.
doi:10.1371/journal.pone.0000399.g003
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(CIMP+/MSI+) under strong pressure to de novo methylation of
both CpG island promoters and repetitive elements and re-
classified colorectal tumors into their known CIMP/MSI groups.
Notably, CIMP+/MSI-and CIMP-/MSI-were mostly clustered
apart, suggesting that the microarray analysis revealed some
special features of each group not seen by LINE-1 bisulfite-
pyrosequecing. For example, SINE repeats show a gradual change
in hypermethylation/hypomethylation according the CIMP/MSI,
with CIMP+/MSI-being an intermediate group. Also, satellite
repeats (mainly represented by centromeric and pericentromeric
repeats) showed a more stable pattern of methylation and it maybe
related to their functional role in chromosome segregation during
cell division. By contrast, Ehrlich et al. [18] found that hypomethy-
lation and hypermethylation are independent in ovarian cancers,
based in the capacity of these alterations to predict the degree of
malignancy in ovarian tumors. However, direct comparisons
of hypomethylation in cancers with and without high levels of
methylation (i.e. CIMP) were not studied. More studies are
necessary to answer why difference repetitive elements classes have
different susceptibility to DNA hypomethylation. In general, our
microarray data suggest that some classes of repetitive elements
can be subject to the same methylation pressures exerted on CpG
islands on CIMP+cancers.
Using LINE-1 methylation as a surrogate for global demethyla-
tion, we found a large variation in methylation levels between
different cancer cell lines, with tissue specificity. Some tissues like
breast, CNS and lung undergo marked LINE-1 demethylation in
cancers in a fairly homogeneous fashion. In other tested tissues,
like colon and leukemia, some cell lines had methylation levels
similar to those exhibited by normal colon and blood tissues, while
others were profoundly demethylated. Although a follow-up study
including normal samples from the same studied tissues is required
to confirm this observation, an analysis performed by Chalicha-
gorn et al. [26] did not showed a marked difference in methylation
between normal samples from various tissues. Similarly to our
results, a previous study by Florl et al. [27] had found a marked
difference between bladder and renal carcinomas, with only the
first exhibiting LINE-1 demethylation. The large variation in
global hypomethylation observed implicates non-stochastic me-
chanisms for this defect, and also suggests a selective advantage for
tumors with severe hypomethylation. Indeed, recent experiments
show that tumor formation is induced in mice after global genomic
hypomethylation [28,29]. Using conditional transgene technology
to reduce expression of DNMT1, Gaudet et al. [28] observed
spontaneous formation of T-cell lymphomas with acquisition of
additional genomic changes. Holm et al. [29] generated mice
that mimic loss of imprinting (LOI), presumed to be due to
hypomethylation, and in these animals tumor formation was also
observed. The causes of such differential demethylation among
cancer of different tissues are unknown, and both genetic and
exposure factors may play roles in this. Profound hypomethyla-
tion, as observed in the cell line K562 and others could be related
to specific loss of function of genes that control methylation of
repetitive elements. Candidate genes are those coding for proteins
that have been described to exert function as ‘‘heterochromatin
guardians’’. For example, the LSH protein, a member of the
SNF2/helicase family proteins, is required for genome-wide
methylation. Knockout mice for the Lsh gene displayed perinatal
mortality and showed marked demethylation of repetitive elements
that is independent from alterations in RNA levels of DNMT1
[30].
In summary, our results show that genome-wide hypomethyla-
tion is highly variable in cancer cells, as is single-copy CpG
island hypermethylation. Both alterations can be found in the
tumors and each one can promote tumorigenesis by independent
processes. Our study also provides evidence for a strong inverse
link between global hypomethylation and microsatellite instability
in cancer.
Figure 4. LINE-1 methylation variability in cancer cell lines. DNA samples
of normal peripheral blood lymphocyte, normal colon mucosa and
sixty-one cell lines from eight different tissues types were investigated
for LINE-1 methylation using bisulfite PCR followed by pyrosequencing.
The normal tissues presented high levels of LINE-1 methylation (above
70% in average), and a large variation in methylation levels was
observed for cancer cell lines, with a minimum methylation density of
6.5% being observed for the leukemia cell line K562. Taken as a group,
leukemia cell lines were moderately demethylated (average 56.1%),
followed by ovary, colon, prostate and lung cancer cell lines (variation
from 49.7% to 35.1%). Central nervous system (CNS), breast and the
one liver cancer cell lines tested were deeply demethylated (bellow
30% in average). Dotted line represents average methylation in normal
controls.
doi:10.1371/journal.pone.0000399.g004
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